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The clinical efficacy of EMLA cream for intravenous catheter placement in client 1 
owned dogs. 2 
  3 
Abstract 4 
Objective 5 
Assessing the reaction of client owned dogs to 6 
 IV catheter placement after applying EMLA or placebo cream for either 30 or 60 minutes. 7 
Study design 8 
Prospective, randomised, blinded, placebo controlled, clinical trial. 9 
Animals 10 
Two hundred and two client owned dogs of various breeds. 11 
Methods 12 
With owner consent, dogs were randomly allocated to one of four treatment groups. Group 1 13 
EMLA 60 minutes; Group 2 EMLA 30 minutes; Group 3 Placebo 60 minutes; Group 4 14 
Placebo 30 minutes. After the cream was applied for the allocated time an IV catheter was 15 
placed and the behavioural reaction of the dog was scored. Reaction score was analysed using 16 
a Kruskall Wallis test followed by Mann Whitney tests of the multiple pairwise comparisons, 17 
with Bonferroni correction. 18 
Results 19 
A large number of dogs, even in the placebo groups, did not react to intravenous catheter 20 
placement. However, the Kruskall Wallis test showed there to be an overall difference 21 
between treatment groups (Chi sq = 11.029, df = 3, p = 0.012). The pairwise comparisons 22 
showed there to be a lower overall reaction score in the EMLA 60 group compared with the 23 
EMLA 30 group and the Placebo 60 group (adjusted p = 0.018 and adjusted p = 0.044, 24 
respectively). 25 
Conclusion and clinical relevance 26 
This study shows that EMLA cream applied for 60 minutes reduces the behavioural reaction 27 
of dogs to IV catheter placement and therefore this intervention can be advocated for routine 28 
use in veterinary medicine to enhance the welfare of dogs undergoing IV catheter placement. 29 
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Introduction 34 
Placement of an intravenous catheter in dogs is a very common procedure in contemporary 35 
veterinary medicine, but one which has been shown to be potentially aversive to the animal 36 
(Chebroux et al. 2015; Flecknell et al. 1990).  37 
The use of EMLA cream, a eutectic mixture of the local anaesthetics lidocaine and 38 
prilocaine, is described in human medicine to desensitise the skin before venepuncture to 39 
make this procedure less aversive (Fetzer 2002; Rogers & Ostrow 2004). Flecknell et al 40 
(1990) showed that the use of EMLA cream reduced the aversiveness of intravenous catheter 41 
placement in laboratory dogs, cats and rabbits. Despite this study showing convincing 42 
evidence of improved welfare, its use has not become standard practice in veterinary 43 
medicine. One of the possible reasons why EMLA cream is not routinely used for IV catheter 44 
placement in veterinary medicine might be the manufacturer’s recommendation of a 60 45 
minutes application time before attempting venepuncture.  In a clinical environment, a 60 46 
minutes waiting period might be considered too long. A study in children (Hopkins et al. 47 
1988) has shown that the application time can be shortened to 30 minutes. However, no data 48 
exist on the efficacy of EMLA cream after a 30 minutes application time in veterinary 49 
medicine. We feel it is worthwhile to study the efficacy of EMLA cream after a 30 minutes 50 
application time, as this shorter waiting period might make the routine use of EMLA cream 51 
before IV catheter placement more feasible in clinical veterinary practice. Also, due to 52 
patient, staff and environmental factors, the effect of EMLA might be less convincing or 53 
absent in a clinical setting compared with the laboratory study of Flecknell et al (1990). We 54 
therefore feel it is worthwhile to study the effect of EMLA in a clinical setting. 55 
The aims of this study were to investigate the efficacy of EMLA cream in a busy 56 
clinical setting and to assess whether there would be a difference in efficacy when using 57 
either a 30 or 60 minutes application time. The objectives were to apply EMLA or a placebo 58 
cream for either 30 or 60 minutes to client owned dogs scheduled for having an intravenous 59 
catheter placed and to score the reaction of the dog to catheter placement. The hypothesis was 60 
that, compared to placebo, EMLA cream would reduce the reaction of dogs to catheter 61 
placement and that shortening the waiting time to 30 minutes would be as effective as a 62 
waiting time of 60 minutes. 63 
 64 
Materials and methods 65 
The study was designed as a randomised, prospective, blinded clinical trial andwas ethically 66 
approved by the institutional animal welfare and ethics review board under the number 67 
VIN/15/049.  68 
Subjects 69 
Two hundred and two (202) client owned dogs of mixed breeds were enrolled on the study 70 
after the owners signed for informed consent. All dogs enrolled, needed IV catheter 71 
placement for further treatment in our hospital. Dogs in which an IV catheter could not be 72 
placed without sedation because of their character were excluded. No other exclusion criteria 73 
were used. Dogs were randomly allocated to one of four experimental groups. Randomisation 74 
was done in blocks of 16, n=4 per experimental group, and achieved by drawing a pre-printed 75 
lot from an opaque envelope.  76 
 A specific power calculation has not been performed for this study, however, 77 
consideration for group size has been performed a priori.  78 
 79 
Procedure 80 
Once allocated to an experimental group, the skin over either the cephalic vein or saphenous 81 
vein was clipped and either EMLA cream (AstraZeneca, Luton, United Kingdom) or a 82 
Placebo (E45 cream, Reckitt Benckiser Healthcare, Slough, United Kingdom) was applied at 83 
a dose of approximately 1.5 grams of cream per 10 cm2 of skin, according to the 84 
manufacturer’s instructions, and covered with an occlusive foil (kitchen cling film, B&M, 85 
Liverpool, United Kingdom). The creams were left on for either 30 or 60 minutes. Treatment 86 
for the different experimental groups was as follows: Group 1: After clipping, EMLA cream 87 
was applied and left on for 60 minutes before placing an IV catheter; Group 2: After clipping, 88 
EMLA cream was applied and left on for 30 minutes before placing an IV catheter; Group 3: 89 
After clipping, Placebo cream was applied and left on for 60 minutes before placing an IV 90 
catheter; Group 4: After clipping, EMLA cream was applied and left on for 30 minutes before 91 
placing an IV catheter.. 92 
After the designated time had elapsed, the skin over the vein was cleared of cream and 93 
prepped with chlorhexidine gluconate (ChloraPrep, BD, Basingstoke, United Kingdom). 94 
Subsequently an intravenous catheter (BD, Basingstoke, United Kingdom, 18 - 24 Gauge) 95 
was placed using a routine technique. Catheters were placed by members of staff (both 96 
veterinary nurses and veterinary surgeons) and students (both veterinary nursing and 97 
veterinary sciences students). Each dog was restrained by the primary investigator (), who 98 
was blinded to group allocation until the final statistical analysis. 99 
 100 
Data recording 101 
The primary outcome recorded was the reaction of the dog to first venepuncture using 102 
the scale as published by Flecknell et al (1990). Reaction 0: no reaction; Reaction 1: slight 103 
movement of limb, tensing of muscles; Reaction 2: Limb withdrawal, attempt to move away; 104 
Reaction 3: Marked attempts to escape, aggressive behaviour, vocalisation. The reaction was 105 
scored by the primary investigator. 106 
Data recorded for each dog were breed, gender, age, weight, body condition score, 107 
and demeanour (1 = friendly, 2 = anxious, 3 = (fear) aggressive). Additional data recorded 108 
were experience level of the catheter placer (novice, moderately experienced, experienced), 109 
outcome of placing a catheter at the prepped site (success, fail), and number of attempts and 110 
time needed to successfully place a catheter. 111 
 112 
Statistical analysis 113 
Continuous data of group demographics and experimental outcomes were analysed by one-114 
way ANOVA, followed by a Tukey post-hoc test when appropriate. The residuals from 115 
parametric analyses were checked visually to ensure that they met the required assumptions 116 
of normality of error and homogeneity of variance. Categorical data on group demographics 117 
were analysed with a Chi-squared test. The primary outcome measure, reaction score, was 118 
analysed using a Kruskall Wallis test followed by Mann Whitney tests of the multiple 119 
pairwise comparisons, with p values adjusted using a Bonferroni correction. Statistical 120 
significance was considered when p < 0.05. The statistics package IBM SPSS Statistics v24 121 
(IBM Corporation, New York) was used for the analysis. 122 
 123 
Results 124 
In total, 202 dogs representing 55 breeds were successfully enrolled, (EMLA60: n=50; 125 
EMLA30: n=51; Placebo 60: n=52; Placebo 30: n=49).  126 
No differences between groups were found for age, weight, gender, body condition score, and 127 
demeanour (table 1). 128 
A contingency table of treatment by reaction score is shown in table 2. The Kruskall 129 
Wallis test showed there to be an overall difference between treatment groups (Chi sq = 130 
11.029, df = 3, p = 0.012). The pairwise comparisons showed there to be a lower overall 131 
reaction score in the EMLA 60 group compared with the EMLA 30 group and the Placebo 60 132 
group (adjusted p = 0.018 and adjusted p = 0.044, respectively). None of the other pairwise 133 
comparisons were significant. 134 
There was no effect of group allocation on the success rate to place an IV catheter at 135 
the prepped site or the total number of attempts needed. However, level of experience did 136 
have a significant effect on success rate (p=0.001), with novice placers having the highest 137 
failure rate (40.9%) compared to moderately experienced (5.8%) and experienced (13.9%). 138 
This was also reflected by the time needed to successfully place an IV catheter which was 139 
significantly longer (p<0.001) for the novice group (211.5 +/- 35.4 seconds), compared with 140 
the moderately experienced (56.5 +/- 11.5 seconds) and experienced (57.8 +/- 8.8 seconds) 141 
groups. 142 
The level of experience of the catheter placer did not differ between groups, and had 143 
no effect on the reaction of the dog to first venepuncture. 144 
 145 
 146 
Discussion 147 
This study shows that EMLA cream applied for 60 minutes reduces the reaction of dogs to IV 148 
catheter placement. This finding is consistent with previous findings of Flecknell et al (1990). 149 
An interesting difference between the previous and present studies is that in the previous 150 
study by Flecknell et al (1990) 16.6 % of dogs undergoing IV catheterisation in the placebo 151 
group did not react to IV catheter placement. In contrast, in the present study 49.0% of dogs 152 
in group Placebo 30 and 61.2% of dogs in group placebo 60 did not react IV catheter 153 
placement. Several potential reasons can be put forward to explain this difference. First, 154 
Flecknell et al studied a population of laboratory beagles who were likely used to the 155 
surroundings and investigators carrying out the study. This study included dogs of different 156 
breeds and backgrounds, inherently introducing variations in behavioural reactions to catheter 157 
placement per se. Second, in the present study the dogs were newly admitted to the hospital 158 
and not familiar with the handlers. The latter may have resulted in a certain level of stress 159 
which might have obscured (sometimes subtle) signs of reaction or could have induced a 160 
temporary state of stress induced analgesia (Bodnar 1986) reducing the aversity of the 161 
procedure. Thirdly, the behavioural scale used to assess the reaction of the dogs can be 162 
considered subjective. As the two studies were carried out by different investigators this 163 
could have introduced differences in outcome. Nevertheless, both studies show that, in a 164 
laboratory and a busy clinical setting respectively, EMLA cream applied for 60 minutes prior 165 
to IV catheter placement reduced the incidence and severity of an aversive reaction to this 166 
procedure in dogs and thus can be advocated to enhance the welfare of canine patients.  167 
 Less reaction of dogs might improve ease of catheter placement, however, the data 168 
from this study show that the success rate of IV catheter placement was not enhanced by the 169 
application of EMLA cream. Conversely, success was not decreased, either. This implies that 170 
the occasionally cited fear of vasoconstriction after application of EMLA cream, leading to 171 
greater difficulty to place an IV catheter (Schreiber et al. 2013), is unjustified.  Other 172 
concerns that have been cited for the use of EMLA cream in the clinical setting are the 173 
development of local anaesthetic toxicity and methaemoglobinaemia. Although not assessed 174 
in this study, previous studies in man and cats have shown that these problems were not 175 
encountered during clinical use of EMLA cream (Wagner et al. 2006; Robieux et al. 1990). 176 
Additionally, in none of the dogs in the present study were signs of local anaesthetic toxicity 177 
observed. We therefore conclude that EMLA cream appears to have no negative side effects 178 
in its clinical use and that fears for such effects should be discarded as reasons to not use 179 
EMLA cream in the clinical setting. 180 
 E45 cream was used as a placebo in this study. The data sheet of E45 cream states 181 
under side effect that ‘Occasionally allergic reaction may occur’. This could make this cream 182 
less suitable to use as a placebo. However, as we have not observed any form of allergic 183 
reaction to either of the creams in any dog during this study, and since E45 cream resembles 184 
EMLA cream in appearance and lacks the local anaesthetic effect, we feel it fulfilled the 185 
purpose of placebo well. Indeed, this cream has been used before as a placebo cream in 186 
human subjects without any reported problems (Speirs et al 2001). 187 
 A limitation of this study was that the level of experience of the catheter placers was 188 
based on a self-judgement. The levels of experience therefore could have been biased by the 189 
overall confidence level of the person asked. However, most people judging themselves as 190 
novice were found to be truly novice as they had placed catheters only once or twice before. 191 
Most of the moderately experienced people were end of year final year veterinary students, 192 
whereas the people who judged themselves as experienced were very confident final year 193 
students, nurses and anaesthetists. We therefore feel that the judgment of the level of 194 
experience, although potentially biased, was accurate. 195 
 Novice catheter placers needed more attempts to successfully place an IV catheter 196 
than moderately experienced and experienced ones. This might suggest that the use of EMLA 197 
is particularly useful when inexperienced people perform the procedure. However, as the 198 
level of experience of the catheter placer did not influence the reaction of the dog to first 199 
venepuncture it seems that the use of EMLA cream can be advocated for placers of all levels 200 
of experience. 201 
 A specific power calculation has not been performed for this study, however, 202 
consideration for group size has been performed a priori. In a controlled laboratory study 203 
with a uniform Beagle population, Flecknell et al (1990) demonstrated an effect of EMLA 204 
cream with a sample size of 12 per group. This sets a lower limit for sample size. The 205 
relatively innocuous consequences of the four treatments being applied allowed ready 206 
expansion of sample size. Given the context of the current study which introduced a wide 207 
range of extraneous, uncontrolled error variation, that would be found in a teaching hospital, 208 
with a wide range of dog breeds being treated, sample size was maximised and constrained 209 
only by the number of suitable dogs that were seen within the time limits of the study. 210 
In conclusion, this is the first clinical study on the use of EMLA cream in dogs, and it 211 
provides evidence that the routine use of EMLA cream in the clinical setting before 212 
placement of and IV catheter in dogs improves their welfare. However, as the cream only 213 
seems to be effective after being applied for 60 minutes, implementation only seems feasible 214 
for elective/non-emergency cases. 215 
 216 
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  254 
Table 1. Demographic data of the dogs enrolled in the four different groups. BCS; body 255 
condition score. Demeanour; 1 = friendly, 2 = anxious, 3 = (fear) aggressive. Experience 256 
level of catheter placer; Nov = Novice, Mod = Moderately experienced, Exp = experienced  257 
 258 
Group EMLA 60 EMLA 30 Placebo 60 Placebo 30 
Age (months)  
mean +/- stdev 
55.5 ± 43.1 57.6 ± 36.2 74.7 ± 41.7 67.4 ± 43.0 
Weight (kg)  
mean +/- stdev 
19.1 ± 15.4 15.9 ± 12.2 18.8 ± 11.4 22.7 ± 15.6 
Gender N 
Male 
Female  
 
31  
19 
 
32  
19  
 
24  
28  
 
31  
18  
BCS (1 – 9) 
median (range) 
5 (4-8) 5 (4-9) 5 (4-8) 5 (3-8) 
Demeanour N 
1 
2 
3 
 
46 
4 
0 
 
43 
8 
0 
 
43 
9 
0 
 
42 
7 
0 
Experience level N 
Nov 
Mod 
Exp 
 
4 
12 
34 
 
7 
8 
36 
 
5 
17 
30 
 
6 
14 
29 
 259 
  260 
Table 2. Reaction of dogs to first venepuncture. Reaction 0: no reaction; Reaction 1: slight 261 
movement of limb, tensing of muscles; Reaction 2: Limb withdrawal, attempt to move away; 262 
Reaction 3: Marked attempts to escape, aggressive behaviour, vocalisation.  263 
 264 
 
Group allocation 
EMLA 
60a 
EMLA 
30b 
Placebo 
60b 
Placebo 
30a,b 
Reaction to first 
attempt 
0 
Count 38 25 27 30 
% 76.0% 49.0% 51.9% 61.2% 
1 
Count 7 10 10 10 
% 14.0% 19.6% 19.2% 20.4% 
2 
Count 3 7 6 6 
% 6.0% 13.7% 11.5% 12.2% 
3 
Count 2 9 9 3 
% 4.0% 17.6% 17.3% 6.1% 
Total 
Count 50 51 52 49 
% 100.0% 100.0% 100.0% 100.0% 
Groups with different letters
(a or b)
 are significantly different. 265 
